A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (NCT06456463)

🧪 Interventions in This Study

• Tagraxofusp (DRUG)
• Venetoclax (DRUG)
• Azacitidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

• University of California, Los Angeles — Los Angeles, California
• Stanford Health Care — Stanford, California
• University of Miami — Miami, Florida
• AdventHealth Cancer Institute — Orlando, Florida
• University of Chicago — Chicago, Illinois
• Dana Farber Cancer Institute (DFCI) — Boston, Massachusetts
• Massachusetts General Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Henry Ford Health System Brigitte Harris Cancer Pavillion — Detroit, Michigan
• Washington University - Siteman Cancer Center — St Louis, Missouri
• John Theurer Cancer Center - Hackensack Meridian Health — Hackensack, New Jersey
• Rutgers Cancer Institute — New Brunswick, New Jersey
• Roswell Park Cancer Institute — Buffalo, New York
• North Shore University Hospital — Manhasset, New York
• NYU Langone Health — New York, New York
• Columbia University Irving Medical Center — New York, New York
• Novant Health Presbyterian Medical Center — Charlotte, North Carolina
• Novant Health Derrick L Davis Cancer Center — Winston-Salem, North Carolina
• Cleveland Clinic Foundation — Cleveland, Ohio
• Sydney Kimmel (Thomas Jefferson University) — Philadelphia, Pennsylvania
• Sarah Cannon, the Cancer Institute of HCA Healthcare — Nashville, Tennessee
• Tennessee Oncology — Nashville, Tennessee
• Baylor Scott & White Health — Dallas, Texas
• University of Texas MD Anderson Cancer Center — Houston, Texas
• Concord Repatriation General Hospital — Concord, New South Wales

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.